Expertise in
27
conditions

Dr. Dian Y. Wang

Radiation Oncology
Rush University Medical Group
1620 W Harrison St, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
27
conditions
Rush University Medical Group
1620 W Harrison St, 
Chicago, IL 
OverviewInsuranceLocationsClinical Research

Overview

Dian Wang is a Radiation Oncologist in Chicago, Illinois. Dr. Wang is highly rated in 27 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Prostate Cancer, Familial Prostate Cancer, Vaginectomy, and Prostatectomy. Dr. Wang is currently accepting new patients.

His clinical research consists of co-authoring 103 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in IL
Hospital Affiliations
Rush Oak Park Hospital
Rush University Medical Center
Languages Spoken
English
Mandarin
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

RUSH UNIVERSITY MEDICAL GROUP
1620 W Harrison St, Chicago, IL 60612
Other Locations
RUSH UNIVERSITY MEDICAL GROUP
520 S Maple Ave, Fl 3, Oak Park, IL 60304
RUSH UNIVERSITY MEDICAL GROUP
1700 W Van Buren St, Chicago, IL 60612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Registry of Retroperitoneal, Abdominal, Pelvic and Truncal Sarcoma Patients Treated with Permanently Implantable LDR CivaSheet® to Evaluate the Safety and Feasibility Over 5 Years
Registry of Retroperitoneal, Abdominal, Pelvic and Truncal Sarcoma Patients Treated with Permanently Implantable LDR CivaSheet® to Evaluate the Safety and Feasibility Over 5 Years
Enrollment Status: Recruiting
Publish Date: February 25, 2025
Intervention Type: Device
Study Phase: Phase 4
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
Prospective Evaluation of Multi-Parametric MRI Guided Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer
Prospective Evaluation of Multi-Parametric MRI Guided Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Doxorubicin, Ifosfamide, Pazopanib
Study Phase: Phase 2/Phase 3
A Phase II, Double-Blinded, Placebo Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-androgen Therapy With Apalutamide in Recurrent Prostate Cancer
A Phase II, Double-Blinded, Placebo Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-androgen Therapy With Apalutamide in Recurrent Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2024
Intervention Type: Drug, Radiation, Procedure
Study Drug: MDM2 Inhibitor KRT-232
Study Phase: Phase 1
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I)
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I)
Enrollment Status: Active_not_recruiting
Publish Date: November 29, 2024
Intervention Type: Biological, Drug, Radiation
Study Drugs: Gonadotrophin releasing hormone, Niraparib
Study Phase: Phase 2
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features
Enrollment Status: Active_not_recruiting
Publish Date: October 16, 2024
Intervention Type: Radiation, Drug
Study Drugs: Enzalutamide, Bicalutamide, GnRH analog
Study Phase: Phase 2
Phase II Trial of Concurrent, Split Course Chemoradiation Followed by Durvalumab (MEDI4736) in Poor Risk And/or Elderly Patients with Newly Diagnosed Stage III Non-small Cell Lung Cancer
Phase II Trial of Concurrent, Split Course Chemoradiation Followed by Durvalumab (MEDI4736) in Poor Risk And/or Elderly Patients with Newly Diagnosed Stage III Non-small Cell Lung Cancer
Enrollment Status: Suspended
Publish Date: October 15, 2024
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Radiation
Study Phase: Phase 3
View 10 Less Clinical Trials

103 Total Publications

Balancing Local and Systemic Control in Esophageal Cancer.
Balancing Local and Systemic Control in Esophageal Cancer.
Journal: Annals of surgical oncology
Published: December 17, 2024
Similar Doctors
Expertise in
35
conditions
Dr. Vinai Gondi
Radiation Oncology
Expertise in
35
conditions
Dr. Vinai Gondi
Radiation Oncology

Northwestern Medical Faculty Foundation

675 N Saint Clair St, 
Chicago, IL 
 (2.8 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vinai Gondi is a Radiation Oncologist in Chicago, Illinois. Dr. Gondi is highly rated in 35 conditions, according to our data. His top areas of expertise are Brain Tumor, Astrocytoma, Glioblastoma, and Metastatic Brain Tumor. Dr. Gondi is currently accepting new patients.

Expertise in
13
conditions
Dr. Gaurav Marwaha
Radiation Oncology
Expertise in
13
conditions
Dr. Gaurav Marwaha
Radiation Oncology

Rush University Medical Group

1700 W Van Buren St, 
Chicago, IL 
 (0.2 mi)
312-563-2875
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gaurav Marwaha is a Radiation Oncologist in Chicago, Illinois. Dr. Marwaha is highly rated in 13 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma.

Expertise in
21
conditions
Dr. Matthew M. Harkenrider
Radiation Oncology
Expertise in
21
conditions
Dr. Matthew M. Harkenrider
Radiation Oncology

Loyola University Medical Center

2160 S 1st Ave, 
Maywood, IL 
 (8.7 mi)
708-216-9000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Harkenrider is a Radiation Oncologist in Maywood, Illinois. Dr. Harkenrider is highly rated in 21 conditions, according to our data. His top areas of expertise are Endometrial Cancer, Cervical Cancer, Lung Cancer, Small Cell Lung Cancer (SCLC), and Prostatectomy. Dr. Harkenrider is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile